294 related articles for article (PubMed ID: 16181138)
1. Poly(ADP-ribose)polymerase inhibition - where now?
Woon EC; Threadgill MD
Curr Med Chem; 2005; 12(20):2373-92. PubMed ID: 16181138
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
3. Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain.
Poitras MF; Koh DW; Yu SW; Andrabi SA; Mandir AS; Poirier GG; Dawson VL; Dawson TM
Neuroscience; 2007 Aug; 148(1):198-211. PubMed ID: 17640816
[TBL] [Abstract][Full Text] [Related]
4. Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG).
Steffen JD; Coyle DL; Damodaran K; Beroza P; Jacobson MK
J Med Chem; 2011 Aug; 54(15):5403-13. PubMed ID: 21692479
[TBL] [Abstract][Full Text] [Related]
5. PARG Inhibitors and Functional PARG Inhibition Models.
Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M
Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death.
Ying W; Sevigny MB; Chen Y; Swanson RA
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12227-32. PubMed ID: 11593040
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.
Harrision D; Gravells P; Thompson R; Bryant HE
Front Mol Biosci; 2020; 7():191. PubMed ID: 33005627
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose): PARadigms and PARadoxes.
Bürkle A; Virág L
Mol Aspects Med; 2013 Dec; 34(6):1046-65. PubMed ID: 23290998
[TBL] [Abstract][Full Text] [Related]
9. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
11. Natural inhibitors of poly(ADP-ribose) polymerase-1.
Banasik M; Stedeford T; Strosznajder RP
Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
Virág L; Szabó C
Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
[TBL] [Abstract][Full Text] [Related]
13. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice.
Cozzi A; Cipriani G; Fossati S; Faraco G; Formentini L; Min W; Cortes U; Wang ZQ; Moroni F; Chiarugi A
J Cereb Blood Flow Metab; 2006 May; 26(5):684-95. PubMed ID: 16177811
[TBL] [Abstract][Full Text] [Related]
15. Poly (ADP-ribose) polymerase-1 (PARP-1) as immune regulator.
Laudisi F; Sambucci M; Pioli C
Endocr Metab Immune Disord Drug Targets; 2011 Dec; 11(4):326-33. PubMed ID: 21476963
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) degradation by post-nuclear extracts from human cells.
Rossi L; Denegri M; Torti M; Poirier GG; Ivana Scovassi A
Biochimie; 2002 Dec; 84(12):1229-35. PubMed ID: 12628300
[TBL] [Abstract][Full Text] [Related]
17. Altered poly(ADP-ribose) metabolism impairs cellular responses to genotoxic stress in a hypomorphic mutant of poly(ADP-ribose) glycohydrolase.
Gao H; Coyle DL; Meyer-Ficca ML; Meyer RG; Jacobson EL; Wang ZQ; Jacobson MK
Exp Cell Res; 2007 Mar; 313(5):984-96. PubMed ID: 17276427
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase inhibitors.
Southan GJ; Szabó C
Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of phenolic hydrazide hydrazones as potent poly(ADP-ribose) glycohydrolase (PARG) inhibitors.
Islam R; Koizumi F; Kodera Y; Inoue K; Okawara T; Masutani M
Bioorg Med Chem Lett; 2014 Aug; 24(16):3802-6. PubMed ID: 25042255
[TBL] [Abstract][Full Text] [Related]
20. The role of NADPH oxidase and neuronal nitric oxide synthase in zinc-induced poly(ADP-ribose) polymerase activation and cell death in cortical culture.
Kim YH; Koh JY
Exp Neurol; 2002 Oct; 177(2):407-18. PubMed ID: 12429187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
